Can Fite Biopharma Ltd ADR (CANF) Stock Analysis

Can Fite Biopharma Ltd ADR (CANF) is a publicly traded company in the HEALTHCARE sector. It trades at $3.24, carries a market capitalization of $6.94M. This page summarizes the public market data, fundamentals, and frequently asked questions for CANF, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $3.24
• Market Cap: $6.94M
• EPS: $-10.75
• 52-Week High: $23.40
• 52-Week Low: $2.83

Market Sentiment

Can Fite Biopharma Ltd ADR currently has a Neutral sentiment score of 0.02.

About Can Fite Biopharma Ltd ADR

Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical company headquartered in Petah-Tikva, Israel, focused on developing innovative small molecule therapeutics targeting a range of serious illnesses, including cancer, liver and inflammatory diseases, COVID-19, and erectile dysfunction. With a robust pipeline anchored by clinical trials, Can-Fite is committed to addressing unmet medical needs through its proprietary drug candidates. The company’s technology platform leverages t...

GNG Research Analysis

GNG Research scores Can Fite Biopharma Ltd ADR (CANF) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CANF.

Frequently Asked Questions

Does CANF pay dividends?

Can Fite Biopharma Ltd ADR (CANF) does not currently pay a regular dividend.

What is CANF's market cap?

Can Fite Biopharma Ltd ADR (CANF) has a market capitalization of $6.94M with a current stock price of $3.24.